Trial Profile
A trial to investigate the efficacy and biomarkers of bevacizumab activity for neurofibromatosis type 2 (NF2) -associated symptomatic vestibular schwannomas (VS).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Acoustic neuroma
- Focus Therapeutic Use
- 04 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology